MarketCap
ICON Public Limited Company ICLR
$ 169.34
0.02%
Facebook
X
Telegram
ICON Public Limited Company Revenue | ICLR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ICON Public Limited Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.25 B | 8.19 B | 8.05 B | 7.74 B | 5.48 B | 2.8 B | 2.81 B | 2.6 B | 1.76 B | 1.67 B | 1.57 B | 1.5 B | 1.34 B | 1.12 B | 946 M | 900 M | 888 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.25 B | 888 M | 3.39 B |
Quarterly Revenue ICON Public Limited Company
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2009-Q4 | 2008-Q4 | 2007-Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.06 B | 2.03 B | 8.25 B | 2.08 B | 2.02 B | 2 B | 8.19 B | 2.03 B | 2.12 B | 2.09 B | 8.05 B | 2.06 B | 2.02 B | 1.98 B | - | - | - | 1.9 B | - | 1.87 B | 871 M | 858 M | - | 702 M | 620 M | 715 M | - | 710 M | 695 M | 675 M | - | 655 M | 642 M | 620 M | - | 440 M | 431 M | 432 M | - | 420 M | 411 M | 401 M | - | 395 M | 389 M | 388 M | - | 388 M | 376 M | 350 M | - | 340 M | 334 M | 317 M | - | 286 M | 277 M | 252 M | - | 241 M | 233 M | 229 M | 900 M | 888 M | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.25 B | 229 M | 1.35 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.81 | 1.63 % | $ 91.2 K |  USA |
 |
Biodesix
BDSX
|
88.5 M | $ 27.49 | 1.95 % | $ 208 M | USA |
 |
Biomerica
BMRA
|
4.45 M | $ 2.4 | 5.96 % | $ 7 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.35 | 10.66 % | $ 7.35 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
540 M | $ 11.67 | 5.68 % | $ 123 M |  China |
 |
Bioventus
BVS
|
568 M | $ 13.22 | 1.85 % | $ 881 M | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 52.37 | 4.21 % | $ 2.79 B | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 1.14 | 1.79 % | $ 1.52 M | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 269.48 | 0.06 % | $ 13.4 B | USA |
 |
Castle Biosciences
CSTL
|
344 M | $ 33.22 | 2.74 % | $ 963 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 239.32 | 1.83 % | $ 26.6 B | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 202.7 | 1.28 % | $ 144 B | USA |
 |
DarioHealth Corp.
DRIO
|
22.4 M | $ 7.1 | 2.31 % | $ 28.3 M |  Israel |
 |
Fulgent Genetics
FLGT
|
323 M | $ 20.56 | 0.54 % | $ 633 M | USA |
 |
Guardant Health
GH
|
982 M | $ 165.87 | 5.39 % | $ 20.8 B | USA |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 509.72 | 0.99 % | $ 41 B | USA |
 |
Illumina
ILMN
|
4.34 B | $ 207.94 | 0.72 % | $ 32.2 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 264.81 | 1.16 % | $ 45.5 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 314.56 | 0.95 % | $ 26.2 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 100.27 | 0.02 % | $ 6.77 B | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 591.17 | 0.62 % | $ 17.1 B | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 287.94 | 1.01 % | $ 26.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
824 M | $ 3.74 | 9.36 % | $ 346 M | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 5.68 | 0.98 % | $ 4.47 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 18.27 | 5.51 % | $ 2.34 B | USA |
 |
Neogen Corporation
NEOG
|
870 M | $ 11.87 | 0.72 % | $ 2.58 B | USA |
 |
National Research Corporation
NRC
|
137 M | $ 22.14 | 4.83 % | $ 496 M | USA |
 |
Natera
NTRA
|
2.31 B | $ 339.13 | 3.1 % | $ 46.4 B | USA |
 |
OPKO Health
OPK
|
148 M | $ 1.55 | 0.38 % | $ 1.16 B | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.36 | 4.23 % | $ 408 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 25.15 | 2.28 % | $ 23.8 B |  Niderland |
 |
Personalis
PSNL
|
69.6 M | $ 16.3 | 0.52 % | $ 1.45 B | USA |
 |
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 8.88 | 1.95 % | $ 371 M | USA |
 |
Neuronetics
STIM
|
149 M | $ 2.89 | 5.61 % | $ 191 M | USA |
 |
Thermo Fisher Scientific
TMO
|
44.6 B | $ 611.62 | 0.3 % | $ 231 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Twist Bioscience Corporation
TWST
|
377 M | $ 136.05 | 6.94 % | $ 8.14 B | USA |
 |
VolitionRx Limited
VNRX
|
1.73 M | $ 0.31 | 0.34 % | $ 39 M |  Singapore |
 |
Waters Corporation
WAT
|
932 M | $ 407.54 | 1.67 % | $ 24.3 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B | USA |
 |
Meridian Bioscience
VIVO
|
333 M | - | - | $ 1.49 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | Israel |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |